AHA 2021: AXIOMATIC-TKR: Patients Treated with Milvexian Show Reduced Rate of Venous Thromboembolism

Подробнее о видео

Watch the full video on Radcliffe Cardiology here:

Dr Jeffrey Weitz (Thrombosis & Atherosclerosis Research Institute, Ontario, CA) presents the results of the Axiomatic-TKR Study, a phase II dose-ranging study that aims to examine the effect of Milvexian versus Enoxaparin in the treatment of venous thromboembolism in patients undergoing total-knee replacement surgery. The study met its efficacy criteria, where the rate of thromboembolism was significantly reduced in the patient group who were taking Milvexian, suggesting the drug's antithrombotic effects on patients.

Discussion points:

1. Rationale of this Study
2. Study Design and Patient Cohort
3. Key Findings
4. Take Home Messages
5. Next Steps

Recorded remotely from Ontario, 2021.

Radcliffe Cardiology is a dynamic, digitally-focused producer & publisher of Cardiovascular, Renal and Metabolic (CVRM) content for physicians worldwide. We aim to assist in the continuous education of physicians within the cardiology fraternity, generating a range of clinical content through collaboration with leading cardiologists from around the globe.